Evidence map›Paper›PMID 25096780›Full record

ArticleJournal of biomedical science2014

Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.

Rita U Ostrovskaya, Yulia V Vakhitova, Uliyana Sh Kuzmina, Milyausha Kh Salimgareeva, Liana F Zainullina, Tatiana A Gudasheva, Vener A Vakhitov, Sergey B Seredenin

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rita U OstrovskayaZakusov Institute of Pharmacology RAS, Baltiyskaya 8, 125315, Moscow, Russia. rita.ostrovskaya@gmail.com.
Yulia V VakhitovaInstitute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect Oktyabrya, 71, 450054, Ufa, Russia. juvv73@gmail.com.
Uliyana Sh KuzminaInstitute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect Oktyabrya, 71, 450054, Ufa, Russia. miph@anrb.ru.
Milyausha Kh SalimgareevaInstitute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect Oktyabrya, 71, 450054, Ufa, Russia. miph@anrb.ru.
Liana F ZainullinaInstitute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect Oktyabrya, 71, 450054, Ufa, Russia. miph@anrb.ru.
Tatiana A GudashevaZakusov Institute of Pharmacology RAS, Baltiyskaya 8, 125315, Moscow, Russia. tata-sosnovka@mail.ru.
Vener A VakhitovInstitute of Biochemistry and Genetics Ufa Scientific Centre RAS, Prospect Oktyabrya, 71, 450054, Ufa, Russia. vakhitov@anrb.ru.
Sergey B SeredeninZakusov Institute of Pharmacology RAS, Baltiyskaya 8, 125315, Moscow, Russia. niipharm@mail.ru.
Institute of Biochemistry and Genetics of Ufa Scientific Centre · RUInstitute of Pharmacology Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNoopept (N-phenyl-acetyl-L-prolylglycine ethyl ester) was constructed as a dipeptide analog of the standard cognition enhancer, piracetam. Our previous experiments have demonstrated the cognition restoring effect of noopept in several animal models of Alzheimer disease (AD). Noopept was also shown to prevent ionic disbalance, excitotoxicity, free radicals and pro-inflammatory cytokines accumulation, and neurotrophine deficit typical for different kinds of brain damages, including AD. In this study, we investigated the neuroprotective action of noopept on cellular model of AD, Aβ 25-35-induced toxicity in PC12 cells and revealed the underlying mechanisms.

resultsThe neuroprotective effect of noopept (added to the medium at 10 μM concentration, 72 hours before Аβ 25-35) was studied on Аβ 25-35-induced injury (5 μM for 24 h) in PC12 cells. The ability of drug to protect the impairments of cell viability, calcium homeostasis, ROS level, mitochondrial function, tau phosphorylation and neurite outgrowth caused by Аβ 25-35 were evaluated. Following the exposure of PC12 cells to Аβ 25-35 an increase of the level of ROS, intracellular calcium, and tau phosphorylation at Ser396 were observed; these changes were accompanied by a decrease in cell viability and an increase of apoptosis. Noopept treatment before the amyloid-beta exposure improved PC12 cells viability, reduced the number of early and late apoptotic cells, the levels of intracellular reactive oxygen species and calcium and enhanced the mitochondrial membrane potential. In addition, pretreatment of PC12 cell with noopept significantly attenuated tau hyperphosphorylation at Ser396 and ameliorated the alterations of neurite outgrowth evoked by Аβ25-35.

conclusionsTaken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway. Moreover, neuroprotective properties of noopept likely include its ability to decrease tau phosphorylation and to restore the altered morphology of PC12 cells. Therefore, this nootropic dipeptide is able to positively affect not only common pathogenic pathways but also disease-specific mechanisms underlying Aβ-related pathology.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsApoptosisCell SurvivalDipeptidesDisease Models, AnimalHumansNeuroprotective AgentsPC12 CellsPeptide FragmentsPhosphorylationRatstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (25-35)Dipeptidesethyl phenylacetyl-Pro-GlyMapt protein, ratNeuroprotective AgentsPeptide Fragmentstau Proteins

Identifiers

PMID25096780
PMCPMC4422191
OpenAlexW2152355553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.